Oral JAK Inhibitors in Adolescent Vitiligo: A Real-World Retrospective Study on Treatment Response and Recurrence

This dataset contains supplementary material for the manuscript entitled "Oral JAK Inhibitors in Adolescent Vitiligo: A Real-World Retrospective Study on Treatment Response and Recurrence" (JAAD-D-25-04902). It includes detailed treatment outcomes and safety profiles of baricitinib, upadacitinib, and tofacitinib in 84 adolescent patients with vitiligo, as presented in Table 2 of the main manuscript. The data support the findings that each JAK inhibitor presents distinct therapeutic characteristics, informing individualized therapy selection.